Atherosclerosis - Pipeline Insight, 2024

This “Atherosclerosis - Pipeline Insight, 2024,” report provides comprehensive insights about 25+ companies and 25+ pipeline drugs in Atherosclerosis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Atherosclerosis Understanding

Atherosclerosis: Overview

Plaque (fatty deposits) build up in arteries is called atherosclerosis. These deposits are made up of cholesterol, fatty substances, cellular waste products, calcium and fibrin (a clotting material in the blood). As plaque builds up, the wall of the blood vessel thickens. This narrows the channel within the artery - reducing blood flow. Atherosclerosis is a slow, lifelong progression of changes in the blood vessels that may start in childhood and get worse faster with the age. Atherosclerosis usually doesn't cause any symptoms until blood supply to an organ is reduced. When this happens, symptoms vary, depending on the specific organ involved: Heart - Symptoms include the chest pain of angina and shortness of breath, sweating, nausea, dizziness or light-headedness, breathlessness or palpitations. Brain - When atherosclerosis narrows brain arteries, it can cause dizziness or confusion; weakness or paralysis on one side of the body. Abdomen - When atherosclerosis narrows the arteries to the intestines, there may be dull or cramping pain in the middle of the abdomen. There is no cure for atherosclerosis, but treatment can slow or halt the worsening of the disease. The major treatment goal is to prevent significant narrowing of the arteries so that symptoms never develop and vital organs are never damaged.

Atherosclerosis - Pipeline Insight, 2024 report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Atherosclerosis pipeline landscape is provided which includes the disease overview and Atherosclerosis treatment guidelines. The assessment part of the report embraces, in depth Atherosclerosis commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Atherosclerosis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Atherosclerosis R&D. The therapies under development are focused on novel approaches to treat/improve Atherosclerosis.

Atherosclerosis Emerging Drugs Chapters

This segment of the Atherosclerosis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Atherosclerosis Emerging Drugs

Aloricumab: Sanofi/ Regeneron Alirocumab is a fully-human monoclonal antibody targeting proprotein convertase subtilisin kexin type 9 (PCSK9) that is being co-developed by Regeneron. Am­gen los­es ap­peal in patent suit against Sanofi/Regeneron’s Praluent. Am­gen los­es ap­peal in patent suit against Sanofi/Regeneron’s Praluent. The drug is in registration phase for the treatment of patients withAtherosclerosis.

VB 201: VBL Therapeutics The lead drug from the lecinoxoids platform, VB-201, is an oral small molecule. VB 201 is an immune-response modifier that acts by reducing the chemokine-mediated migration of monocytes to the damaged organ. The drug is currently in Phase II stage of development for the treatment of patients with Atherosclerosis.

Atherosclerosis: Therapeutic Assessment

This segment of the report provides insights about the different Atherosclerosis drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Atherosclerosis

There are approx. 25+ key companies which are developing the therapies for Atherosclerosis. The companies which have their Atherosclerosis drug candidates in the most advanced stage, i.e. Registration include, Sanofi/ Regeneron.

Phases

This report covers around 25+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Atherosclerosis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical.

Molecule Type

Products have been categorized under various Molecule types such as

• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Atherosclerosis: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Atherosclerosis therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Atherosclerosis drugs.

Atherosclerosis Report Insights

• Atherosclerosis Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Atherosclerosis Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Atherosclerosis drugs?
• How many Atherosclerosis drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Atherosclerosis?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Atherosclerosis therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Atherosclerosis and their status?
• What are the key designations that have been granted to the emerging drugs?

This product will be delivered within 1-3 business days.